Larotrectinib

Larotrectinib Brand Name– VITRAKVI

What is Larotrectinib

Larotrectinib is a kinase inhibitor approved for adult and pediatric patients 28 days and older with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Larotrectinib is tissue agnostic for treatment of solid tumors with this genetic mutation.

Serious adverse reactions that can occur with larotrectinib use include neurotoxicity and hepatotoxicity.

Indications

• neurotrophic receptor tyrosine kinase-positive solid tumors

For the treatment of neurotrophic receptor tyrosine kinase-positive solid tumors

NOTE: Larotrectinib has been designated an orphan drug by the FDA for the treatment of solid tumors with NTRK-fusion proteins.

Side Effects

1. abdominal pain
2. abdominal pain
3. anemia
4. anemia
5. anorexia
6. anorexia
7. arthralgia
8. arthralgia
9. asthenia
10. back pain
11. back pain
12. cerebral edema
13. constipation
14. constipation
15. cough
16. dehydration
17. delirium
18. diarrhea
19. diarrhea
20. dizziness
21. dizziness
22. dysarthria
23. dyspnea
24. dyspnea
25. elevated hepatic enzymes
26. elevated hepatic enzymes
27. encephalopathy
28. enterocutaneous fistula
29. fatigue
30. fatigue
31. fever
32. fever
33. GI obstruction
34. GI perforation
35. headache
36. hyperamylasemia
37. hypertension
38. hypertension
39. hypoalbuminemia
40. hypoalbuminemia
41. hyponatremia
42. infection
43. jaundice
44. leukemia
45. memory impairment
46. myalgia
47. myalgia
48. nasal congestion
49. nausea
50. nausea
51. neurotoxicity
52. neurotoxicity
53. neutropenia
54. neutropenia
55. new primary malignancy
56. paresthesias
57. pericardial effusion
58. peripheral edema
59. pleural effusion
60. syncope
61. tremor
62. vomiting
63. vomiting
64. weakness
65. weight gain
66. weight gain

Monitoring Parameters

• LFTs
• pregnancy testing

Contraindications

• breast-feeding
• contraception requirements
• driving or operating machinery
• hepatic disease
• infertility
• male-mediated teratogenicity
• pregnancy
• pregnancy testing
• reproductive risk